Prosthetic Valve Endocarditis in Surgical vs. Transcatheter Aortic Valve Replacement

Transcatheter and surgical aortic valve replacement carry the same overall risk for prosthetic valve endocarditis.

Transcatheter aortic valve replacement (TAVR) is increasingly used to treat patients with critical aortic valve stenosis who are deemed too high risk to undergo surgical valve replacement (SAVR). The relative risk for prosthetic valve endocarditis (PVE) in patients undergoing TAVR versus SAVR has not been definitively studied in multicenter trials. To examine this risk, researchers examined a pooled cohort of 8530 patients from PARTNER trials and registries.

Adjudicated definite PVE occurred in 107 patients based on the modified Duke criteria. Follow-up varied depending on the trial; mean follow-up was 2.7 years. The incidence of PVE in TAVR was 5.21 per 1000 person-years (95% confidence interval, 4.26–6.38), which was not statistically diff…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases